PMN310 interim Phase I-B data show safety and biomarker signals
PMN310, a differentiated antibody targeting toxic amyloid-beta oligomers, showed strong interim safety and biomarker signals in a Phase I-B Alzheimer’s study; top-line results are expected in Q1 2027 and Phase III planning is underway.
PMN310, a differentiated antibody targeting toxic amyloid-beta oligomers, showed interim safety and biomarker signals in a phase I-B Alzheimer's study. Top-line results are expected in Q1 2027. The company said it is well-funded, is advancing a robust pipeline and is planning for phase III and commercial preparations.